P rimary percutaneous coronary intervention (PCI) is the recommended default reperfusion strategy for patients seen in the first hours after the onset of ST-segment-elevation myocardial infarction (STEMI).
10 years, evidence has shown that fibrinolytic treatment should not be used as standalone therapy but rather as part of a pharmacoinvasive strategy, with the patients brought to PCI-capable facilities after fibrinolysis for semiurgent coronary angiography and secondary PCI when necessary. Recently, the Strategic Reperfusion Early after Myocardial Infarction (STREAM) study showed that the major cardiac events at 30 days with such a pharmaco-invasive strategy in patients with first medical contact within 3 hours of symptom onset compared favorably with those of primary PCI performed beyond 60 minutes of initial diagnosis. 3 Whether this strategy can still compete with primary PCI in terms of very long-term survival remains uncertain. The French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) 2005 is a nationwide multicenter survey of patients hospitalized for acute MI (AMI) at the end of 2005. 4 The population included was characterized in great detail, and long-term follow-up is currently underway. We therefore assessed the 5-year outcome of STEMI patients included in the registry according to the reperfusion strategy used at the acute stage.
Methods Population
The population and methods of the FAST-MI registry have been described in detail elsewhere. 4, 5 Briefly, the objective of the study was to collect comprehensive data on the management and outcome of consecutive patients admitted to intensive care units for definite AMI over a 1-month period in France, regardless of the type of institution to which the patients were admitted (ie, university hospitals, public hospitals, or private clinics, with or without on-site catheterization facilities). Of the 374 centers that treated patients with AMI at that time, 223 (60%) participated in the study. The physicians in charge of the patients took care of them according to their usual practice and independently from the study.
Patient Selection
All consecutive adult (≥18 years of age) patients admitted to the participating centers for a 1-month period beginning on October 1, 2005 , were included in the registry if they had elevated serum markers of myocardial necrosis higher than twice the upper limit of normal for creatine kinase, creatine kinase-MB, or elevated troponins; if they had symptoms compatible with AMI, ECG changes on at least 2 contiguous leads with pathological Q waves (at least 0.04 second), or persisting ST-segment elevation or depression >0.1 mV; and if they consented to participate in the study. The time from the onset of symptoms to admission to the intensive care unit had to be <48 hours. Patients who died very soon after admission and for whom cardiac markers were not measured were included if they had compatible signs or symptoms associated with typical ST-segment changes. Likewise, patients dying very early, before they could give informed consent, were included in the database unless the next of kin objected.
Patients with iatrogenic MI, defined as MI occurring within 48 hours of a therapeutic procedure, and those in whom AMI diagnosis was invalidated in favor of another diagnosis were excluded from the survey.
For the present analysis, only patients with persisting ST-segment elevation or a presumably new left bundle-branch block on their initial ECG and with a time from symptom onset to first call ≤12 hours were included.
Patients gave informed consent for participation in the survey and follow-up. During the whole survey period, 249 patients presenting with either STEMI or non-STEMI declined participation; no information could be collected for those patients. 
Data Collection
All data were recorded by dedicated research technicians on computerized case record forms sent to each of the centers at least once a week. Cardiovascular history, current medications at the time of admission, risk factors, in-hospital clinical course, including maximal Killip class, and initial diagnostic and therapeutic management were recorded for each patient.
Prehospital fibrinolysis was defined as the administration of fibrinolytic therapy before hospital admission. Primary PCI was defined as emergency coronary angiography with the intention to perform a percutaneous intervention, whatever the means used (ie, balloon angioplasty, thrombus aspiration, stent implantation with bare metal or drug-eluting stents). Therefore, we included in this group the small percentage of patients (5%) who underwent emergency coronary angiography in order to perform primary PCI, but in whom the procedure was not actually performed because it was considered clinically inadvisable (eg, open artery, small occluded vessel, or difficult coronary anatomy and limited amount of myocardium at stake). The "no reperfusion" group was made up of patients who received neither fibrinolytic treatment nor emergency angiography.
Time to first call was defined as the time when the patient or his/ her relatives first sought medical attention. For patients directly using the mobile intensive care units system (Service d'Aide Médicale Urgente), time to first call was defined as the time to the initial call to the centralized regulation center, not as the time of ambulance arrival. Time to reperfusion was defined as time to intravenous injection of fibrinolytics or time to arterial puncture in patients treated with primary PCI. Thrombolysis in Myocardial Infarction (TIMI) flow before and after the PCI procedures was recorded as reported by the clinicians.
We defined a "STREAM-like" population as the subgroup of patients with time from onset to call ≤180 minutes and treated with either fibrinolysis or primary PCI beyond 90 minutes of first call. The threshold of 90 minutes from initial call to PCI was considered to be the best surrogate for the threshold of 60 minutes from diagnostic ECG to expected primary PCI, which was used in the STREAM trial, because it took into account the time needed from initial call to arrival of the mobile intensive care unit and actual diagnosis, in addition to the time from diagnosis to primary PCI.
End Point
The outcome variable used for the present study was all-cause mortality at 5 years. Follow-up was centralized at the French Society of Cardiology, and dedicated research technicians contacted both the physicians and the patients after checking the patients' vital status in municipal registers. The rates of patients lost to follow-up were 0.3% at 1 year, 1.9% at 3 years, and 4.1% at 5 years. At 5 years, the percentage of patients lost to follow-up was 4.5% for the no reperfusion group, 4.0% for the fibrinolysis group, and 3.8% for the primary PCI group.
Statistical Analysis
All continuous variables are described as their mean±SD or as median and interquartile range. All categorical variables are described using absolute and relative frequency distributions. Comparisons between groups used unpaired t tests or nonparametric Mann-Whitney tests for continuous variables and χ 2 tests for discrete variables. Survival curves were generated with the Kaplan-Meier method and compared by use of log-rank tests. Patients lost to follow-up were kept in the analyses and censored at the time they were last known to be alive.
Two sets of analyses were performed.
Cox Multivariate Analysis
A backward Cox multivariate analysis was used for assessing predictors of 5-year mortality, with a value of P=0.05 for inclusion and P=0.10 for exclusion. The cumulative hazard functions for each covariable were computed to assess proportionality, and collinearity by guest on July 26, 2017
http://circ.ahajournals.org/ Downloaded from was verified by calculating variance inflation factors. The candidate variables included in the multivariate analyses were selected ad hoc on the basis of their physiological relevance and potential to be associated with long-term mortality: age; sex; type and region of institution; time to first call; history of heart failure; history of diabetes mellitus; hypertension; current smoking; prior AMI; stroke; peripheral artery disease; comorbidity; anemia on admission; early use of aspirin, clopidogrel, low-molecular-weight heparin, or glycoprotein IIB/ IIIa inhibitors; and presence of triple-vessel coronary artery disease in the model comparing the 2 reperfusion strategies. Three analyses were performed: an analysis using a 3-modality variable for reperfusion (no reperfusion, fibrinolysis, primary PCI), a second analysis to directly compare the 2 reperfusion modalities after the exclusion of patients who did not receive reperfusion therapy, and a third using a 3-modality variable (prehospital lysis, in-hospital lysis, primary PCI) in the population of patients who received reperfusion therapy.
Propensity Score-Matched Analyses
A second type of analysis was made using propensity scores to match 1 fibrinolysis for 1 primary PCI patient. The propensity score was calculated from a multivariate binary logistic regression analysis using the same baseline variables as for the Cox analysis, also including time to first call, use of the emergency medical system, and medications used before the index episode, but not the early use of glycoprotein IIb/IIIa inhibitors and initial admission to a center with catheterization laboratory, which differed too much between the 2 treatment strategies to enable cohorts of a reasonable size to be built. Model fits were satisfactory (Hosmer-Lemeshow P value=0.53, C statistic=0.74 for the overall population model; Hosmer-Lemeshow P value=0.40, C statistic=0.84 for the STREAM-like population). Three types of adjustments were made to calculate adjusted hazard ratios (HRs): an adjustment including only the type of center of admission (with versus without catheterization laboratory), an adjustment also including the use of glycoprotein IIb/IIIa inhibitors within 24 hours of admission, and an adjustment additionally including use of coronary angiography in the fibrinolytic-treated patients. Finally, a further propensity score was calculated, restricting the population to patients admitted to centers with catheterization laboratories. The analyses were performed with IBM-SPSS version 20.0 and NCSS 9 software. For all tests, a value of P<0.05 was considered significant.
Results

Baseline Characteristics, Early Management, and In-Hospital Complications
Of 1492 patients with STEMI and a time to first call ≤12 hours from symptom onset, 447 (30%) received fibrinolytic therapy (20% had prehospital fibrinolysis), 583 (39%) had intended primary PCI, and 462 (31%) received no reperfusion therapy. The baseline characteristics of the patients according to reperfusion therapy are reported in Table 1 and Table I in the online-only Data Supplement. Patients who did not get reperfusion therapy were older and more frequently had a history of cardiovascular disease and comorbidity and an overall higher risk profile; patients treated with either fibrinolysis or intended primary PCI had similar Global Registry of Acute Coronary Events (GRACE) scores, but many of their baseline characteristics differed. In particular, patients receiving fibrinolytic treatment had called earlier after symptom onset than those receiving primary PCI. Among fibrinolytic-treated patients, only fibrin-specific agents were used (tenecteplase in 78%); 96% underwent subsequent coronary angiography (38% within 3 hours, 23% between 3 and 24 hours, and 39% beyond 24 hours of lytic administration), and 84% had a PCI. Among patients with intended primary PCI, 95% actually underwent the intended procedure. Patients with fibrinolysis less often received low-molecular-weight heparin, clopidogrel, or glycoprotein IIb/IIIa inhibitors. Initial TIMI grade 3 flow was seen more frequently in lytic-treated patients. Final TIMI grade 3 flow was more commonly achieved after primary PCI (90%) than in the totality of patients undergoing coronary angiography after fibrinolysis (83%): 96% after routine PCI, 90% after rescue PCI, and 36% when PCI was not performed.
There was a numeric excess of reinfarction, stroke, and ventricular fibrillation with the fibrinolytic-based strategy and an excess of major bleeding, transfusion, and cardiogenic shock with primary PCI. However, none of the in-hospital complications differed significantly for the 2 reperfusion strategies ( Table 2) .
Five-Year Outcome According to the Use and Type of Reperfusion Therapy
Crude 5-year survival was 65% in patients without reperfusion therapy, 88% for patients with fibrinolysis, and 84% for those with primary PCI. Among patients receiving fibrinolytic therapy, survival was 90% for prehospital fibrinolysis and 85% for in-hospital fibrinolysis (Figure 1 ).
Adjusted HR (95% confidence interval [CI]) for 5-year death in reference to patients receiving no reperfusion therapy was 0.57 (95% CI, 0.43-0.74) for primary PCI and 0.48 (95% CI, 0.35-0.68) for the pharmaco-invasive strategy. Direct comparison of the 2 reperfusion techniques showed a nonsignificant trend favoring fibrinolytic treatment (HR, 0.73; 95% CI, 0.50-1.06; P=0.10). When the timing of administration of fibrinolytic therapy was taken into consideration, prehospital administration was associated with lower 5-year mortality (HR, 0.57; 95% CI, 0.36-0.88), whereas in-hospital administration was associated with a trend to higher 5-year mortality (HR, 1.19; 95% CI, 0.72-1.96) compared with primary PCI. In lytic-treated patients, rescue PCI was associated with a trend to increased 5-year mortality compared with routine PCI after lytic treatment (14% versus 11%; adjusted HR, 1.68; 95% CI, 0.85-3.33). Subgroup analyses showed no interaction between type of reperfusion therapy and age, sex, time from symptom onset to call, or diabetes mellitus ( Figure I in the online-only Data Supplement).
In the STREAM-like population, 5-year survival was 88% with the fibrinolysis-based strategy and 81% with intended primary PCI (P=0.009), with an adjusted HR of 0.63 (95% CI, 0.41-0.98; P=0.039). When only prehospital fibrinolysis was considered, 5-year survival with prehospital fibrinolysis was 89% (HR versus primary PCI, 0.56; 95% CI, 0.34-0.91; P=0.019; Figure II in the online-only Data Supplement).
The propensity score-matched cohorts yielded 348 pairs of patients in the whole population and 257 pairs in the STREAMlike population, with each set of pairs having similar baseline characteristics except for admission to PCI centers and use of glycoprotein IIb/IIIA inhibitors (Table II in Survival was also similar in the cohorts from the STREAM-like population (87% for fibrinolysis and 85% for primary PCI) before and after adjustment (Figure 2 ).
Discussion
To the best of our knowledge, this is the first real-world study comparing 5-year outcomes in STEMI patients with regard to reperfusion therapy with either primary PCI or fibrinolytic treatment as part of a pharmaco-invasive approach (ie, fibrinolytic treatment followed by generalized use of coronary angiography and a high rate of secondary PCI). In a previous analysis of the FAST-MI 2005 data, we observed similar outcomes up to 1 year in STEMI patients treated with either method of reperfusion. 4 The question of whether these initial results changed with a longer follow-up deserved clarification. Five-year survival was high in patients who had received reperfusion therapy with either primary PCI or a pharmaco-invasive approach, with approximately two thirds of the patients receiving fibrinolytic treatment in the prehospital setting. As expected, patients who did not receive reperfusion therapy had a much higher mortality. In a comparison of the 2 reperfusion strategies, the results achieved with the pharmaco-invasive approach were at least as good as those with an intended primary PCI strategy. In patients who called early, Cox multivariate analysis showed a significant survival advantage for the pharmaco-invasive strategy compared with primary PCI beyond 90 minutes of first call; this was not confirmed, however, in the propensity score-matched populations in which just a trend favoring the pharmaco-invasive approach was found. Based on numerous randomized, controlled trials performed mainly in the 1990s, current guidelines recommend primary PCI as the strategy of choice for patients with STEMI, provided that it can be implemented in due course.
1,2 Most of these seminal trials, however, compared primary PCI with standalone fibrinolytic therapy. 6 More recent data have shown trends to improved results with rescue PCI in patients with no evidence of reperfusion after fibrinolytic treatment, as well as routine coronary angiography within hours of the administration of fibrinolytic treatment, even when fibrinolysis appears successful. [7] [8] [9] [10] [11] The Comparison of Angioplasty and Prehospital Thrombolysis in Acute Myocardial Infarction (CAPTIM) trial, although underpowered, has suggested that prehospital fibrinolytic therapy with the patients brought to PCI-capable centers and with one third undergoing rescue angioplasty could do at least as well as primary PCI up to 5 years after the initial episode, 12 and a pooled analysis of the CAPTIM and Which Early ST-Elevation Myocardial Infarction Therapy (WEST) trials found a reduction in 1-year mortality with fibrinolysis in patients seen early. 13 In contrast, the Assessment of the Safety and Efficacy of a New Treatment Strategy With Percutaneous Coronary Intervention (ASSENT-4 PCI) trial 14 showed an excess of thrombotic events with fibrinolysis-facilitated PCI (ie, when PCI was performed immediately after the delivery of fibrinolytic treatment), suggesting that, when signs of reperfusion are present, waiting for at least 3 hours before performing PCI in fibrinolytic-treated patients might be advisable, given the known prothrombotic effects of fibrinolytic agents and the higher residual thrombus burden observed in lytic-facilitated PCI. 15 In the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial, 1-year mortality was numerically but not significantly lower in patients treated with combination therapy (half-dose reteplase and abciximab followed by urgent PCI) compared with primary PCI, suggesting a potential role for potent antiplatelet agents in this setting. 16 Although the technique of fibrinolysis has evolved toward an integrated pharmaco-invasive approach, interventional cardiologists have also gained experience in treating patients in the context of AMI, and new medications or techniques are now commonly used in such patients, likely leading to improved clinical results. [17] [18] [19] Overall, similar progress has been observed since the mid-1990s in the outcomes of STEMI patients treated with either primary PCI or fibrinolysis. 20 Analyzing the long-term clinical results of both methods of reperfusion, as they are currently used in the real world, therefore seemed appropriate.
Very recently, the STREAM trial compared a pharmaco-invasive strategy with primary PCI in patients seen early after symptom onset in whom primary PCI could not be performed within 1 hour of the qualifying ECG. 3 Only the 30-day results are known, which show a nonsignificant difference in the trial primary end point (death, reinfarction, shock, and congestive heart failure) favoring the pharmacoinvasive strategy, with no difference in all-cause mortality and with an increased risk of intracranial bleeding, found mainly before the protocol was amended to reduce the doses of fibrinolytic therapy in elderly patients. Our data in patients seen early who could not have had a timely primary PCI are in line with the 30-day results of the STREAM trial. They do not suggest, however, a progressively increasing benefit of the pharmaco-invasive strategy over time, despite the facts that more patients had initial TIMI grade 3 flow when receiving fibrinolytic treatment and that the pharmaco-invasive strategy was associated with significantly (albeit slightly) higher left ventricular ejection fraction and less use of loop diuretics at discharge. The immediate benefit in terms of early culprit artery patency might indeed be offset by less favorable post-PCI results, as we found in our patients and as was observed in the ASSENT 4-PCI trial. 15 In the STREAM-like population, however, as was the case in the STREAM trial, post-PCI TIMI flow was similar with the 2 strategies.
Our study suffers the usual limitations of observational studies. Although we prospectively collected a great number of variables, including details of the medications administered, the possibility of confounding factors that might not have been recorded cannot be excluded. In this regard, it is exemplary that we found discordant results between the conventional Cox multivariate regression analysis and propensity score matching in the population that corresponded to the population of the STREAM trial, namely superiority of the pharmaco-invasive strategy with the Cox analysis, but no significant difference for the propensity score-matched cohorts. Although this discordance might be driven by lack of power in the propensity score-matched cohorts, our data cannot be considered to formally prove equivalence (or superiority of one) of the 2 reperfusion methods. There was no indication, however, of the superiority of primary PCI, whatever the statistical techniques used. The time from qualifying ECG to reperfusion was not collected in the FAST-MI 2005 registry, which led us to use a time from call to reperfusion of >90 minutes to define the STREAM-like population as a surrogate for the 60-minute threshold from ECG to reperfusion used in the STREAM trial. Changing our threshold to 60 or 120 minutes, however, did not substantially modify our results.
Conclusions
In a real-world setting on a nationwide scale, we observed high 5-year survival rates for STEMI patients, provided that they were treated with either primary PCI or a pharmaco-invasive strategy (initial fibrinolytic therapy followed by coronary angiography and high rates of subsequent PCI). The pharmaco-invasive strategy yielded results that were at least as good as those of primary PCI. Overall, in the absence of contraindication and considering the potential difficulty of implementing an emergency PCI service available 24 hours a day and 7 days a week in some settings, a pharmaco-invasive strategy seems to represent a safe alternative to primary PCI. 
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